Metabolism of fluoropyrimidines in cancer patients (Part II).

Keiji Yasue(Higashi Nagoya National Hospital), Takeshi Ohkita(Higashi Nagoya National Hospital), Kenji Ina, S Suga(Higashi Nagoya National Hospital), Yoji Murata(Kobe University), Hakutaka Hashizume(Higashi Nagoya National Hospital), Hirohumi Nagai(Higashi Nagoya National Hospital), Yo Horiuchi(Higashi Nagoya National Hospital), Yoshiko Usami(University of Massachusetts Chan Medical School)
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
January 1, 1987
10.3999/jscpt.18.689
Cited by 3

Related Papers

SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef
|Nature|2015|466
Structural Basis for Budding by the ESCRT-III Factor CHMP3
|Developmental Cell|2006|254
Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface
|Biochemical Journal|1993|213
Release of autoinhibition converts ESCRT-III components into potent inhibitors of HIV-1 budding
|Proceedings of the National Academy of Sciences|2006|182
Structural Basis of HIV-1 Tethering to Membranes by the BST-2/Tetherin Ectodomain
|Cell Host & Microbe|2010|152